Recent efficacy studies and FDA-approval for a dual RAF/MEK inhibition approach in BRAF-mutant melanoma is supporting the clinical relevance of this escape mechanism, but significant toxicity concerns remain16, 17. This evidence concerns the gene RAF1 and melanoma.